Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1961 1
1975 1
1977 3
1979 2
1981 3
1982 3
1984 1
1985 1
1987 1
1990 3
1993 1
1994 1
1995 2
1996 3
1999 2
2000 1
2001 2
2002 2
2003 3
2004 1
2005 5
2006 3
2007 4
2008 5
2009 3
2010 6
2011 6
2012 10
2013 7
2014 8
2015 10
2016 5
2017 10
2018 11
2019 8
2020 15
2021 13
2022 21
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.
Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, Khalid S, Hutchings A, Luqmani RA, Watts RA, Merkel PA; DCVAS Study Group. Grayson PC, et al. Among authors: craven a. Ann Rheum Dis. 2022 Mar;81(3):309-314. doi: 10.1136/annrheumdis-2021-221794. Epub 2022 Feb 2. Ann Rheum Dis. 2022. PMID: 35110334
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis.
Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, Khalid S, Hutchings A, Watts RA, Merkel PA, Luqmani RA; DCVAS Investigators. Robson JC, et al. Among authors: craven a. Ann Rheum Dis. 2022 Mar;81(3):315-320. doi: 10.1136/annrheumdis-2021-221795. Epub 2022 Feb 2. Ann Rheum Dis. 2022. PMID: 35110333
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C. Brakedal B, et al. Among authors: craven ar. Cell Metab. 2022 Mar 1;34(3):396-407.e6. doi: 10.1016/j.cmet.2022.02.001. Cell Metab. 2022. PMID: 35235774 Free article. Clinical Trial.
Reply.
Grayson PC, Ponte C, Robson JC, Suppiah R, Judge A, Hutchings A, Craven A, Khalid S, Luqmani RA, Watts RA, Merkel PA. Grayson PC, et al. Among authors: craven a. Arthritis Rheumatol. 2022 Oct;74(10):1725-1726. doi: 10.1002/art.42267. Epub 2022 Aug 30. Arthritis Rheumatol. 2022. PMID: 35713987 No abstract available.
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis.
Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, Khalid S, Hutchings A, Luqmani RA, Watts RA, Merkel PA; DCVAS Study Group. Grayson PC, et al. Among authors: craven a. Arthritis Rheumatol. 2022 Mar;74(3):386-392. doi: 10.1002/art.41982. Epub 2022 Feb 2. Arthritis Rheumatol. 2022. PMID: 35106968
181 results